The results showed that SGLT-2 inhibitors significantly reduced serum uric acid levels in patients with CKD compared with the placebo group (standardized mean difference (SMD): −0.22; 95% CI: −0.42 to −0.03; Grading of Recommendations, Assessment, Development, and Evaluations (GRADE): low). The gene discussed is SLC5A2; the disease is chronic kidney disease.